COVID-19 Impact on Global Gene Therapy for CNS Disorders Market Size, Status and Forecast 2020-2026

July 2020 | 90 pages | ID: C689ED4EE460EN
QYResearch

Abstracts

This report focuses on the global Gene Therapy for CNS Disorders status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for CNS Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Gilead (Kite Pharma)
• Amgen (BioVex)
• Novartis
• Roche (Spark Therapeutics)
• Bluebird Bio

Market segment by Type, the product can be split into

• Ex Vivo
• In Vivo

Market segment by Application, split into

• Hospitals
• Clinics
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Gene Therapy for CNS Disorders status, future forecast, growth opportunity, key market and key players.
• To present the Gene Therapy for CNS Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Gene Therapy for CNS Disorders are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
1.4 Market Analysis by Type
  1.4.1 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Ex Vivo
  1.4.3 In Vivo
1.5 Market by Application
  1.5.1 Global Gene Therapy for CNS Disorders Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Clinics
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy for CNS Disorders Industry Impact
  1.6.1 How the Covid-19 is Affecting the Gene Therapy for CNS Disorders Industry
    1.6.1.1 Gene Therapy for CNS Disorders Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Gene Therapy for CNS Disorders Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Gene Therapy for CNS Disorders Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Gene Therapy for CNS Disorders Market Perspective (2015-2026)
2.2 Gene Therapy for CNS Disorders Growth Trends by Regions
  2.2.1 Gene Therapy for CNS Disorders Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Gene Therapy for CNS Disorders Historic Market Share by Regions (2015-2020)
  2.2.3 Gene Therapy for CNS Disorders Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Gene Therapy for CNS Disorders Market Growth Strategy
  2.3.6 Primary Interviews with Key Gene Therapy for CNS Disorders Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Gene Therapy for CNS Disorders Players by Market Size
  3.1.1 Global Top Gene Therapy for CNS Disorders Players by Revenue (2015-2020)
  3.1.2 Global Gene Therapy for CNS Disorders Revenue Market Share by Players (2015-2020)
  3.1.3 Global Gene Therapy for CNS Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Gene Therapy for CNS Disorders Market Concentration Ratio
  3.2.1 Global Gene Therapy for CNS Disorders Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy for CNS Disorders Revenue in 2019
3.3 Gene Therapy for CNS Disorders Key Players Head office and Area Served
3.4 Key Players Gene Therapy for CNS Disorders Product Solution and Service
3.5 Date of Enter into Gene Therapy for CNS Disorders Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Gene Therapy for CNS Disorders Historic Market Size by Type (2015-2020)
4.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Type (2021-2026)

5 GENE THERAPY FOR CNS DISORDERS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
5.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Gene Therapy for CNS Disorders Market Size (2015-2020)
6.2 Gene Therapy for CNS Disorders Key Players in North America (2019-2020)
6.3 North America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
6.4 North America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Gene Therapy for CNS Disorders Market Size (2015-2020)
7.2 Gene Therapy for CNS Disorders Key Players in Europe (2019-2020)
7.3 Europe Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
7.4 Europe Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

8 CHINA

8.1 China Gene Therapy for CNS Disorders Market Size (2015-2020)
8.2 Gene Therapy for CNS Disorders Key Players in China (2019-2020)
8.3 China Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
8.4 China Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Gene Therapy for CNS Disorders Market Size (2015-2020)
9.2 Gene Therapy for CNS Disorders Key Players in Japan (2019-2020)
9.3 Japan Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
9.4 Japan Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Gene Therapy for CNS Disorders Market Size (2015-2020)
10.2 Gene Therapy for CNS Disorders Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
10.4 Southeast Asia Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

11 INDIA

11.1 India Gene Therapy for CNS Disorders Market Size (2015-2020)
11.2 Gene Therapy for CNS Disorders Key Players in India (2019-2020)
11.3 India Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
11.4 India Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Gene Therapy for CNS Disorders Market Size (2015-2020)
12.2 Gene Therapy for CNS Disorders Key Players in Central & South America (2019-2020)
12.3 Central & South America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
12.4 Central & South America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Gilead (Kite Pharma)
  13.1.1 Gilead (Kite Pharma) Company Details
  13.1.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
  13.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Introduction
  13.1.4 Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2015-2020))
  13.1.5 Gilead (Kite Pharma) Recent Development
13.2 Amgen (BioVex)
  13.2.1 Amgen (BioVex) Company Details
  13.2.2 Amgen (BioVex) Business Overview and Its Total Revenue
  13.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Introduction
  13.2.4 Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  13.2.5 Amgen (BioVex) Recent Development
13.3 Novartis
  13.3.1 Novartis Company Details
  13.3.2 Novartis Business Overview and Its Total Revenue
  13.3.3 Novartis Gene Therapy for CNS Disorders Introduction
  13.3.4 Novartis Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  13.3.5 Novartis Recent Development
13.4 Roche (Spark Therapeutics)
  13.4.1 Roche (Spark Therapeutics) Company Details
  13.4.2 Roche (Spark Therapeutics) Business Overview and Its Total Revenue
  13.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Introduction
  13.4.4 Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  13.4.5 Roche (Spark Therapeutics) Recent Development
13.5 Bluebird Bio
  13.5.1 Bluebird Bio Company Details
  13.5.2 Bluebird Bio Business Overview and Its Total Revenue
  13.5.3 Bluebird Bio Gene Therapy for CNS Disorders Introduction
  13.5.4 Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  13.5.5 Bluebird Bio Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Gene Therapy for CNS Disorders Key Market Segments
Table 2. Key Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
Table 3. Ranking of Global Top Gene Therapy for CNS Disorders Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Ex Vivo
Table 6. Key Players of In Vivo
Table 7. COVID-19 Impact Global Market: (Four Gene Therapy for CNS Disorders Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Gene Therapy for CNS Disorders Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Gene Therapy for CNS Disorders Players to Combat Covid-19 Impact
Table 12. Global Gene Therapy for CNS Disorders Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Gene Therapy for CNS Disorders Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Gene Therapy for CNS Disorders Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Gene Therapy for CNS Disorders Market Share by Regions (2015-2020)
Table 16. Global Gene Therapy for CNS Disorders Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Gene Therapy for CNS Disorders Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Gene Therapy for CNS Disorders Market Growth Strategy
Table 22. Main Points Interviewed from Key Gene Therapy for CNS Disorders Players
Table 23. Global Gene Therapy for CNS Disorders Revenue by Players (2015-2020) (Million US$)
Table 24. Global Gene Therapy for CNS Disorders Market Share by Players (2015-2020)
Table 25. Global Top Gene Therapy for CNS Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for CNS Disorders as of 2019)
Table 26. Global Gene Therapy for CNS Disorders by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Gene Therapy for CNS Disorders Product Solution and Service
Table 29. Date of Enter into Gene Therapy for CNS Disorders Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 32. Global Gene Therapy for CNS Disorders Market Size Share by Type (2015-2020)
Table 33. Global Gene Therapy for CNS Disorders Revenue Market Share by Type (2021-2026)
Table 34. Global Gene Therapy for CNS Disorders Market Size Share by Application (2015-2020)
Table 35. Global Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 36. Global Gene Therapy for CNS Disorders Market Size Share by Application (2021-2026)
Table 37. North America Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 39. North America Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 40. North America Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 41. North America Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 42. North America Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 43. Europe Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 45. Europe Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 47. Europe Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 49. China Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 50. China Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 51. China Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 52. China Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 53. China Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 54. China Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 55. Japan Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 57. Japan Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 59. Japan Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 63. Southeast Asia Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 65. Southeast Asia Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 67. India Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 68. India Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 69. India Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 70. India Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 71. India Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 72. India Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Gene Therapy for CNS Disorders Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Gene Therapy for CNS Disorders Market Share (2019-2020)
Table 75. Central & South America Gene Therapy for CNS Disorders Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Gene Therapy for CNS Disorders Market Share by Type (2015-2020)
Table 77. Central & South America Gene Therapy for CNS Disorders Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Gene Therapy for CNS Disorders Market Share by Application (2015-2020)
Table 79. Gilead (Kite Pharma) Company Details
Table 80. Gilead (Kite Pharma) Business Overview
Table 81. Gilead (Kite Pharma) Product
Table 82. Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 83. Gilead (Kite Pharma) Recent Development
Table 84. Amgen (BioVex) Company Details
Table 85. Amgen (BioVex) Business Overview
Table 86. Amgen (BioVex) Product
Table 87. Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 88. Amgen (BioVex) Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Product
Table 92. Novartis Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 93. Novartis Recent Development
Table 94. Roche (Spark Therapeutics) Company Details
Table 95. Roche (Spark Therapeutics) Business Overview
Table 96. Roche (Spark Therapeutics) Product
Table 97. Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 98. Roche (Spark Therapeutics) Recent Development
Table 99. Bluebird Bio Company Details
Table 100. Bluebird Bio Business Overview
Table 101. Bluebird Bio Product
Table 102. Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2015-2020) (Million US$)
Table 103. Bluebird Bio Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Gene Therapy for CNS Disorders Market Share by Type: 2020 VS 2026
Figure 2. Ex Vivo Features
Figure 3. In Vivo Features
Figure 4. Global Gene Therapy for CNS Disorders Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Gene Therapy for CNS Disorders Report Years Considered
Figure 9. Global Gene Therapy for CNS Disorders Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Gene Therapy for CNS Disorders Market Share by Regions: 2020 VS 2026
Figure 11. Global Gene Therapy for CNS Disorders Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Gene Therapy for CNS Disorders Market Share by Players in 2019
Figure 14. Global Top Gene Therapy for CNS Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for CNS Disorders as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy for CNS Disorders Revenue in 2019
Figure 16. North America Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Gene Therapy for CNS Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Gilead (Kite Pharma) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Gilead (Kite Pharma) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 25. Amgen (BioVex) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Amgen (BioVex) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 27. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Novartis Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 29. Roche (Spark Therapeutics) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche (Spark Therapeutics) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 31. Bluebird Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Bluebird Bio Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2015-2020)
Figure 33. Bottom-up and Top-down Approaches for This Report
Figure 34. Data Triangulation
Figure 35. Key Executives Interviewed